Cure SMA Clinical Care Session 2021: Enduring Activity
JOINTLY PROVIDED BY
University of Wisconsin–Madison Interprofessional Continuing Education Partnershp (ICEP)
and
Cure SMA
TARGET AUDIENCE
This activity is intended for the health care team providers who diagnose and care for people affected by SMA, including physicians, nurse practitioners, physician assistants and nurses, pediatric and adult specialists including neurologists, pulmonologists, rehabilitation medicine, genetics, orthopedic surgery, palliative care, physical and occupational therapists, speech and language pathologists, pharmacists, nutritionists, genetic counselors, social workers, respiratory therapists, and trainees in the above disciplines.
ACTIVITY OBJECTIVES
After completing this activity, participants and their health care team should be better able to:
- Demonstrate knowledge of multidisciplinary team roles and responsibilities in care management to optimize SMA outcomes
- Describe the existing and evolving treatment options for patients with SMA
- Describe the impact of new treatments on the SMA phenotype
- Analyze the treatment options for management of infants with SMA identified by SMA newborn screening
- Demonstrate knowledge risk for mental health complications of SMA
- Describe the application of mental health screening tools for SMA outpatient use
ELEMENTS OF COMPETENCE
This activity has been designed to change learner competence and focuses on the American Board of Medical Specialties areas of patient care and procedural skills, medical knowledge, practice-based learning and improvement, interpersonal and communication skills, professionalism, and systems-based practice. This activity also focuses on the interprofessional competencies of values/ethics for interprofessional practice, interprofessional communication, and teams/teamwork.
The University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and Cure SMA gratefully acknowledge the educational grants provided by Genentech and Novartis Gene Therapies.
PRESENTATIONS AND SPEAKERS | |
Welcome and CMO Update, Mary Schroth, MD | |
Cure SMA Community Database Outcomes, Lisa Belter, MPH | |
Special Session: Ethics, Moderator: Julie Parsons, MD; Panelists: Thomas Crawford, MD, John Brandsema, MD, Bakri Elsheikh, MD; Ethicist: Brian Jackson, MD, MA | |
Single Institution Experience of Nusinersen Treatment of Adult Patients with Spinal Muscular Atrophy, Meghan Moore, PT, DPT, NCS | |
Clinical Efficacy and Safety of Risdiplam Use as Combination Therapy in Spinal Muscular Atrophy (SMA) Patients Post Onasemnogene-Abeparvovec-Xioi (Onasemnogene) and/or Nusinersen Use, Kapil Arya, MBBS, FAAP, FANA, Paul Drake, MD | |
Nusinersen by Subcutaneous Catheter for Spinal Muscular Atrophy, Karlla Brigatti, MS, CGC | |
MUSCULOSKELETAL PANEL | |
A. Bracing for Scoliosis in Spinal Muscular Atrophy: Is It Effective, Brian Snyder, MD, PhD | |
B. 20 Year Experience with Segmental Sublaminar Instrumentation for Guided Growth in Early Onset Scoliosis, Samuel R. Rosenfeld, MD | |
C. Hip Pain Assessment in Patients with Spinal Muscular Atrophy: Prevalence, Intensity, Interference, and Associated Factors, Amy Xu, BS | |
D. Development of a Competency-Based Educational Program for Spinal Muscular Atrophy Physical Therapists (STEP-IN), Jacqueline Montes, PT, EdD | |
Special Session: Mental Health Screening and Management Tools, Moderator: Vamshi Rao, MD; Speakers and Panelists: Pamela Mosher, MD, Vanessa Battista, RN, MS, CPNP-PC, CHPPN, Diane Murrell, LCSW, Al Freedman, PhD | |
SMA NEWBORN SCREENING PANEL | |
A. Integrating a Pilot Newborn Screening for Spinal Muscular Atrophy into the Australian Public Healthcare System, Arlene D'Silva, PhD | |
B. Statewide Newborn Screening for Spinal Muscular Atrophy: The Wisconsin Experience, Mei Baker, MD | |
C. The Clinicians and Families Experience with the First Year of Newborn Screening in Colorado and Wyoming, Melissa Gibbons, MS, CGC | |
D. Investigating the SMA Patient Community's Attitudes Towards Fetal Therapy, Marisa Schwab, MD |
FACULTY
Kapil Arya, MBBS, FAAP, FANA, Associate Professor of Pediatric Neurology, University of Arkansas College of Medicine
Mei Baker, MD, Professor, Pediatrics-Genetics and Metabolism, University of Wisconsin School of Medicine and Public Health
Vanessa Battista, RN, MS, CPNP-PC, CHPPN, NP, Division of Neurology, Children's Hospital of Philadelphia
Lisa Belter, MPH, Cure SMA
John Brandsema, MD, Assistant Professor of Clinical Neurology, Children's Hospital of Philadelphia
Karlla Brigatti, MS, CGC, Research Operations Director, Clinic for Special Children, Pennsylvania
Thomas Crawford, MD, Professor of Neurology, Johns Hopkins School of Medicine
Arlene D'Silva, PhD, Post-Doctoral Researcher, Western Sydney University
Paul Drake, MD, Child Neurology Resident, University of Arkansas College of Medicine
Bakri Elsheikh, MD, Associate Professor of Clinical Neurology, The Ohio State University Wexner Medical Center
Al Freedman, PhD, Licensed Psychologist, Freedman Counseling Associates
Melissa Gibbons, MS, CGC, Assistant Professor, Pediatrics-Clinical Genetics and Metabolism, University of Colorado School of Medicine
Brian Jackson, MD, MA, Assistant Professor of Pediatric Critical Care Medicine; Chair of Ethics Committee, Children's Hospital of Colorado
Jacqueline Montes, PT, EdD, Assistant Professor of Clinical Rehabilitation and Regenerative Medicine, Columbia University Irving Medical Center
Meghan Moore, PT, DPT, NCS, Board-Certified Neurological Clinical Specialist, Johns Hopkins Children's Center
Pamela Mosher, MD, Assistant Professor, Department of Psychiatry, University of Toronto
Diane Murrell, LCSW, Texas Children's Hospital
Julie Parsons, MD, Professor of Clinical Pediatrics and Neurology, Children's Hospital of Colorado
Vamshi Rao, MD, Assistant Professor of Pediatrics (Neurology and Epilepsy), Children's Hospital of Chicago
Samuel Rosenfeld, MD, Clinical Associate Professor, Department of Orthopedic Surgery, Children's Health Orange County, University of California Irvine
Marisa Schwab, MD, General Surgery Resident, University of California San Francisco Medical Center
Brian Snyder, MD, PhD, Professor of Orthopedic Surgery, Boston Children's Hospital
Amy Xu, BS, Medical Student, Johns Hopkins School of Medicine
PLANNERS
Vanessa Battista, RN, MS, CPNP-PC, CHPPN, Palliative Care Pediatric Nurse Practitioner, Children's Hospital of Philadelphia, Philadelphia, PA
William Bell, BS Pharm, MBA, MSCC, RPh, Director of Clinical Client Services, Chalfont, PA
John Brandsema, MD, Pediatric Neuromuscular Neurologist, Children's Hospital of Philadelphia, associated with the Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA
Jin Yun Chen, MS, CGC, Genetic Counselor, Massachusetts General Hospital, Boston, MA
Thomas Crawford, MD, Pediatric Neurologist, Johns Hopkins Hospital, associated with Johns Hopkins University, Baltimore, MD
Bakri Elsheikh, MD, Neurologist, Neuromuscular Medicine, and Clinical Neurophysiology at The Ohio State University Wexner Medical Center, Columbus, OH
Al Freedman, PhD, Psychologist, Independent Practice, Philadelphia, PA
Melissa Gibbons, MS, CGC, Genetic Counselor at Children's Hospital Colorado, Aurora, CO
Jennifer Hubbell, BS, Occupational Therapist, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Becky Hurst-Davis, MS, RD, Pediatric Nutritionist, Intermountain Healthcare, Salt Lake City, UT
Chamindra Konersman, MD, Neurologist, Rady Children's Hospital, associated with the University of California, San Diego, San Diego, CA
Richard Kravitz, MD, Pediatric Pulmonologist and Sleep Medicine Physician, Duke University, Durham, NC
Kristin Krosschell, PT, DPT, Pediatric Physical Therapist, Northwestern University, Chicago, IL
Oren Kupfer, MD, Pediatric Pulmonologist, Children's Hospital Colorado, associated with the University of Colorado School Of Medicine, Denver, CO
Cathy Means, MS, Senior Outreach Specialist, University of Wisconsin School of Medicine and Public Health, Madison, WI
Diane Murrell, LCSW, Social Worker, Texas Children's Hospital, Houston, TX
Leslie Nelson, PT, PhD, OCS, Pediatric Neuromuscular Physical Therapist, Children’s Health, associated with the University of Texas Southwestern, Dallas, TX
Julie Parsons, MD, Pediatric Neurologist, Children's Hospital Colorado, Aurora, CO
Samuel R. Rosenfeld, MD, Orthopedic Surgeon, Children’s Health of Orange County Children's Hospital, Orange, CA
Peter Schochet, MD, Pediatric Pulmonologist, Children’s Health, associated with the University of Texas Southwestern, Dallas, TX
Mary Schroth, MD, Chief Medical Officer, Cure SMA, Elk Grove Village, IL
Edward Smith, MD Pediatric Neurologist, Duke University, Durham, NC
Anne Stratton, MD, Pediatric Physiatrist, Children's Hospital Colorado, associated with the University of Colorado, Denver, CO
Stacey Tarrant, RD, LDN, Nutritionist, Boston Children's Hospital, Boston, MA
Jane Taylor, MD, Pediatric Pulmonologist, UPMC Children's Hospital of Pittsburgh, associated with the University of Pittsburgh School of Medicine, Pittsburgh, PA
Laura Watne, MD, RD, Nutritionist, Children's Hospital Colorado, associated with the University of Colorado, Denver, CO
Elanda Williams, MA, Education Coordinator, Cure SMA, Elk Grove Village, IL
POLICY ON FACULTY AND SPONSOR DISCLOSURE
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters, and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.
*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by, or on, patients. The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.
NAME |
ROLE(S) |
FINANCIAL RELATIONSHIPS DISCLOSURE | DISCUSSION OF UNLABELED/ UNAPPROVED USES OF DRUGS/DEVICES IN PRESENTATION? |
Kapil Arya, MBBS | Presenter | No relevant relationships with ineligible companies to disclose | No |
Mei Baker, MD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Vanessa Battista, RN, MS | Planner, Presenter | AveXis; Biogen; Novartis; PTC Therapeutics, Inc. (All Contractor) | No |
William Bell, PharmD, MBA | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Lisa Belter, MPH | Presenter | No relevant relationships with ineligible companies to disclose | No |
John Brandsema, MD | Planner, Presenter | Alexion Pharmaceuticals; Biogen; Catabasis; CSL Behring; FibroGen; Novartis; PTC Therapeutics, Inc.; Pfizer; Sarepta Therapeutics, Inc.; Summit, WaVe (All Grant); Audentes; Biogen Idec; Cytokinetics; Genentech; Momenta Pharmaceuticals, Inc.; Novartis Pharma; NS Pharma; PTC Therapeutics, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock; WaVe (All Contractor) | No |
Karlla Brigatti, MS, CGC | Presenter | Biogen, Inc.; Novartis (Grant); Novartis (Contractor) | Yes |
Jin Yun Chen, MS, CGC | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Thomas Crawford, MD | Planner, Presenter | Biogen, Inc.; Genentech USA, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock (All Contractor) | No |
Arlene D’Silva, PhD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Paul Drake, MD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Bakri Elsheikh, MD | Planner, Presenter | Biogen (Contractor and Grant); Genentech (Contractor) | No |
Albert Freedman, PhD | Planner, Presenter | Genentech; Novartis (Both Contractor) | No |
Melissa Gibbons, MS, CGS | Planner, Presenter | Biogen; Novartis (Both Grant) | No |
Jennifer Hubbell, BS | Planner | No relevant relationships with ineligible companies to disclose | No |
Becky Hurst-Davis, MS, RD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Brian Jackson, MD, MA | Presenter | No relevant relationships with ineligible companies to disclose | No |
Chamindra Konersman, MD | Planner | Biogen, Inc.; Novartis Pharma; Sarepta Therapeutics, Inc. (All Contractor) | N/A |
Richard Kravitz, MD | Planner | AveXis; Biogen, Inc.; Santhera (All Contractor) | N/A |
Kristin Krosschell, PT, DPT | Planner | ASPA Therapeutics; Biogen; Genentech; Novartis; (All Contractor); Biogen (Grant) | N/A |
Oren Kupfer, MD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Cathy Means, MS | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Jacqueline Montes, PT, EdD | Presenter | Biogen, Inc.; F. Hoffmann-LaRoche; Genentech USA, Inc.; Sarepta Therapeutics, Inc.; Scholar Rock (All Contractor) | No |
Meghan Moore, PT, DPT | Presenter | Biogen, Inc.; Genentech (Both Contractor) | No |
Pamela Mosher, MD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Diane Murrell, LCSW | Planner, Presenter | No relevant relationships with ineligible companies to disclose | No |
Leslie Nelson | Planner | Avexis; Biogen, Inc.; F. Hoffmann-La Roche; Genentech; Novartis; Scholar Rock (All Contractor) | N/A |
Julie Parsons, MD | Planner, Moderator | Biogen; Genentech; Novartis; Scholar Rock (All Contractor) | No |
Vamshi Rao, MD | Moderator | Avexis; Biogen; Capricor; Genentech; NSpharma; PTC Therapeutics, Inc.; RegenxBio; Sarepta Therapeutics, Inc.; Scholar Rock; Watermark (All Contractor) | No |
Samuel Rosenfeld, MD | Planner, Presenter | OrthoPediatrics Corp. (Contractor) | No |
Peter Schochet, MD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Mary Schroth, MD | Planner, Medical Director | Audentes Therapeutics (Contractor) | No |
Marisa Schwab, MD | Presenter | No relevant relationships with ineligible companies to disclose | No |
Edward Smith, MD | Planner | Biogen; Genentech; Novartis (All Contractor) | N/A |
Brian Snyder, MD, PhD | Presenter | Alcyone; OrthoPediatrics Corp. (Both Contractor) | No |
Anne Stratton, MD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Stacey Tarrant, RD, LDN | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Jane Taylor, MD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Laura Watne, MD, RD | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Elanda Williams, MA | Planner | No relevant relationships with ineligible companies to disclose | N/A |
Amy Xu, BS | Presenter | No relevant relationships with ineligible companies to disclose | No |
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and Cure SMA. The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. | |
Credit Designation Statements | |
American Medical Association (AMA)The University of Wisconsin-Madison ICEP designates this enduring material for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. | |
American Board of PediatricsSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 5.5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. | |
American Board of Internal MedicineSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. | |
American Academy of Physician Assistants (AAPA)The University of Wisconsin-Madison ICEP has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.5 AAPA Category 1 CME credits. Approval is valid until November 1, 2022. PAs should only claim credit commensurate with the extent of their participation. | |
| American Nurses Credentialing Center (ANCC)The University of Wisconsin–Madison ICEP designates this enduring material for a maximum of 5.5 ANCC contact hours. |
Accreditation Council for Pharmacy Education (ACPE)The University of Wisconsin–Madison ICEP designates this enduring knowledge-based activity for 5.5 hours/0.55 CEUs of CPE credit. Credit can be earned by successfully completing the activity, the assessment, and the evaluation. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. University Activity Number (UAN) JA0000358-9999-21-070-H04-P. 5.5 hours/0.55 CEUs | |
American Psychological Association (APA)(CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. | |
ASWB Approved Continuing Education (ACE) Social Work CreditAs a Jointly Accredited Organization, the University of Wisconsin–Madison ICEP is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The University of Wisconsin–Madison ICEP maintains responsibility for this course. Social workers completing this course receive 5.5 enduring continuing education credits. | |
Wisconsin Physical Therapy Association (WPTA)This activity has been approved by the APTA Wisconsin for 5.50 credits (Approval Number 18328). | |
Wisconsin Occupational Therapy Association (WOTA)This activity has been approved by WOTA for 5.5 credits. | |
| Continuing Education Units (CEUs)The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for .55 CEUs or 5.5 hours. |
Available Credit
- 5.50 AAPA Category 1 CME
- 5.50 MOC: ABIM Medical Knowledge Points (Part II)
- 5.50 MOC: ABP Lifelong Learning Points (Part II)
- 5.50 ACPE Contact Hours - Pharmacist
- 5.50 AMA PRA Category 1 Credit™
- 5.50 ANCC Contact Hours
- 5.50 APA CE Credits
- 5.50 Occupational Therapy (OT) CE Contact Hours
- 5.50 Physical Therapy Contact Hours
- 5.50 University of Wisconsin–Madison Continuing Education Hours
- 5.50 Approved for AMA PRA Category 1 Credit™
Required Hardware/software
Computer, tablet, or smartphone with AV capabilities.
Free, current version of Chrome, Firefox, Safari, or Edge. Some older browsers and Internet Explorer could produce error messages or not display the content correctly.
Free, current version of Adobe Acrobat Reader or other .pdf reader